This section contains information and education for healthcare professionals and has been developed as a comprehensive resource providing information on TRK fusion proteins as a potential therapeutic target for selected patients across multiple tumour types.
This section was created in 2019 and updated in 2022.
There are three modules in this section. They are aimed at medical oncologists and pathologists including molecular and surgical pathologists. Geneticists, pharmacists, and public health professionals may also find this information useful. We recommend that Module 1 is selected first, but the modules can be selected in any order.
By pursuing, you confirm that you have read and understand the disclaimer.
Last updated: June 2022